Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancerStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: 9 May 2024
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 May 2024
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 September 2024
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 31 March 2025
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)Status:In developmentProgramme:NICE guidelineExpected publication date: TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC